Although there weren’t many large-scale partnerships as in previous years, Korean biopharma firms were involved in a broad range of deals across diverse therapeutic areas in 2020, with ADCs, oncology and domestic alliances emerging as key trends. 

Serum Institute has struck a partnership with Dynavax and Aurobindo Pharma with US-based company COVAXX for new vaccine candidates while Bharat Biotech has tied up with Ocugen to explore marketing of its existing contender, Covaxin, in the US.

J&J executive emphasizes that fast-tracked development of COVID-19 vaccines does not come with any corners cut around safety. Indian partner Biological E also outlines the complexities in manufacturing and believes that the candidates from J&J, AstraZeneca and others will be more suitable in profile and price terms to contain the pandemic globally.

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker